[null, null, {"document_url": "http://thischangedmypractice.com/2015/02/", "unformatted_src": "http://thischangedmypractice.com/files/2015/02/dry-AMD-360x187.jpg", "src": "http://thischangedmypractice.com/files/2015/02/dry-AMD-360x187.jpg", "formatted_filename": "dry AMD", "alt_text": "Age-Related Macular Degeneration", "rendered_width": 198, "rendered_height": 132}, null, {"document_url": "http://thischangedmypractice.com/2015/02/", "unformatted_src": "http://med-fom-tcmp.sites.olt.ubc.ca/files/2018/01/ubccpd-email-tagline.png", "src": "http://med-fom-tcmp.sites.olt.ubc.ca/files/2018/01/ubccpd-email-tagline.png", "formatted_filename": "ubccpd email tagline", "alt_text": "UBC CPD logo and website"}, null]
» This Changed My Practice » 2015 » February

 Incretin Safety: What is the Evidence?

By Dr. Breay Paty on February 18, 2015

Nausea can be a common side effect of GLP-1 receptor agonist, which can sometimes be dose limiting. However, this usually improves with time. As a new class of agents, evidence for the long-term safety of incretins is still emerging. Most of the safety questions involve cardiovascular (CV) risk, as well as pancreatitis and pancreatic cancer.
 Age-Related Macular Degeneration: New treatments that changed my practice

By Dr. Suren Sanmugasunderam on February 3, 2015

There are 2 major forms of Age-Related Macular Degeneration (ARMD). The dry form is characterized by drusen, pigmentary mottling and retinal and retinal pigment epithelial atrophy. The wet form is characterized by choroidal neovascular membranes (CNVM).

